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Dear Friends,
When discoveries from medical research migrate to the art and science of medicine, powerful progress comes to the quality
of care for the patients of Children’s Mercy Hospitals and Clinics. Our reputation for medical excellence annually attracts to our
two hospitals and 35 clinics hundreds of thousands of patients and families for various diagnostic and treatment services from
a remarkably talented staff of medical doctors, nurses, and clinicians. Although the devotion of our professionals to the care and
treatment of our patients can be vividly seen by our families on a daily basis, less visible but equally important is the devotion of
those professionals to the enterprises of research and education. The pages of this report will tell you of our progress there and
will keep our research colleagues around the world informed as we bring well-deserved recognition to the professional leaders
whose research activities bring new knowledge to the practice of good medicine.
At Children’s Mercy, our collaborative approach to research brings together medical doctors, physician scientists, nurses,
biomedical scientists, research technicians and postdoctoral fellows, all leaders in their fields, working as a team to advance
the frontiers of medical science and the healing arts. A clinician treating a patient in one of our clinics may very well serve as
a critical member of a team of research investigators seeking to discover scientific breakthroughs that could someday serve to
benefit that patient and countless others challenged by the same condition. An MD scientist devoted to research in the laboratory
may be called upon to offer expertise in consultation with a medical doctor in service at the bedside of a patient whose critical
health conditions require insights from professionals working on research relevant to that patient’s treatment.
The medical doctor treating a patient in the hospital or performing surgery in an operating room may also be of service as
a medical educator. That doctor’s students may be undergraduate medical school students, medical residents, fellows or peers
learning state-of-the-art techniques empowered by research conducted in our laboratory or Children’s Mercy’s clinical setting.
Our commitment to education plays a significant role in developing new talent to join in our research enterprise. The number of
postdoctoral fellowship programs for physicians is expanding rapidly, and all of these require a research component. By offering
outstanding opportunities in both education and research, Children’s Mercy is becoming a global leader in preparing the next
generation of innovators in pediatric medicine.
The fact that a majority of our doctors participate in the enterprises of research and education stimulates throughout our
institution an appetite for new knowledge. In the process, research brings vital nutrients to the practice of good medicine and
helps us recruit valuable professional talent—seasoned senior scientists and promising young investigators alike—to Kansas City
to join our team. You will see that over the past year we have made promising progress in all of these endeavors.
Not only is that progress enabled by the sharp focus of our program, but also by our dedication to collaboration. At Children’s
Mercy Hospitals and Clinics, cross-disciplinary and well-integrated health care teams of professionals treat not just a disease,
but the whole patient. Just as integrated, cross-disciplinary health care teams thrive on collaboration, so too does research. This
collaboration is embedded in the DNA of our culture, which enhances the productivity of our partnership activities with other
academic and pediatric health care institutions.
Scientific/research breakthroughs that lead to the cure or improved management of a disease rarely take place on the
occasion of a single event in a laboratory or clinical setting. By its very nature, research is incremental, with progress achieved
through meticulous steps disciplined by the totality of scientific knowledge and directed here, of course, by research leaders who
provide focus, add talent, and exercise reasoned judgment. Through modern technology and through commitments to increased
collaboration with other leading institutions of pediatric medicine throughout the nation, we are now taking these steps with
greater precision and with an even greater intensity of focus.
During the past year, Children’s Mercy Hospital has used its considerable strengths in genomics and clinical pharmacology
to introduce Pharmacogenomics as a clinical service for our patients. By using a patient’s DNA to obtain information about
the activity of drug-metabolizing enzymes, drug transporters and receptors; and linking this information in some cases to
measurements of drug levels in the blood; our pediatric clinical pharmacologists can individually tailor drug treatment regimens
for specific patients that maximize their therapeutic potential and improve safety. Along with our partners associated with the
Institute for Pediatric Innovation, we have exciting plans for expansion of this area of our research program in the future.
We could not close this letter without acknowledging with the deepest gratitude the remarkable generosity of our benefactors,
institutional funders, and grant-making partners, all of whom have provided the financial resources necessary for us to carry out
our research mission and report on the progressive developments of the previous year. We thank them for their support, and we
thank you in advance for your engagement through absorbing the information on the pages of this report and through continuing
to demonstrate your partnership with Children’s Mercy Hospitals and Clinics into the future.
Sincerely,

Randall L. O’Donnell, PhD					

Gregory Kearns, PharmD, PhD




Expansion Provides Limitless
Opportunities
The long-range expansion plan unveiled by Children’s
Mercy in 2007 calls for more than tripling the amount of space
dedicated to research in the next 15 years, including a new, stateof-the-art laboratory that will house a novel, new program in pediatric
personalized medicine.
Phase I of the expansion plan calls for one floor of research space in
a new nine-story building to be constructed by 2011, with a second floor
of shelled-in space for possible future expansion. In addition to serving
as the home for the personalized medicine initiative, this new space
will provide expanded wet laboratory space for new faculty investigators
working within the program and also, the offices of the Department of
Medical Research. Phase III of the plan includes two additional floors of
research space, with the final plan expanding the hospital’s total space
dedicated to research from its current 44,800 square feet to more than
158,000 square feet by 2020.
“A research program runs on people, researchers who are attracted
to Children’s Mercy by the promise of what they can accomplish here,”
says Gregory Kearns, PharmD, PhD, Chairman of the Department
of Medical Research and Associate Chairman of the Department of
Pediatrics. “But you can’t make that promise to them unless you can
also offer them the state-of-the-art laboratories and facilities that this
expansion plan will make possible for our program. This growth in space
and resources will open up limitless new possibilities for expanding
current programs, recruiting new physician and biomedical scientists
and initiating the kind of new research endeavors that will enable
Children’s Mercy to be the leader in translating scientific discoveries into
effective new avenues of pediatric care.”



A research program is measured not only by the work taking
place within its laboratories, but also how the representatives
of that program extend their expertise “beyond the bench.” And
in Children’s Mercy’s case, that measure extends literally throughout the
world.
For example, Gregory Kearns, PharmD, PhD, Chairman of the
Department of Medical Research at Children’s Mercy, who was selected to
serve as the United States representative to the pediatric subcommittee
of the Essential Medicines Committee of the World Health Organization
(WHO). This subcommittee is developing a first-ever list of “essential
pediatric medicines” for use throughout the world. Dr. Kearns also has
been appointed to a permanent position on the overall Essential Medicines
Committee.
WHO also has invited Dr. Kearns to serve as a pediatric clinical
pharmacologist member on a new special task force which is looking at
the drugs currently available to treat children with tuberculosis and will
create a blueprint for the development of new, pediatric formulations of
antituberculosis drugs that will be used to treat this disease worldwide.
Dr. Kearns also serves on the U.S. Food and Drug Administration’s Clinical
Pharmacology Advisory Committee, which is increasing its focus on testing
new drugs specifically for use by children and developing new drugs
designed for children’s unique needs.



Gregory Kearns, PharmD, PhD

Reaching Beyond Hospital Walls



New Researc h

Engineering Hope for Heart Defects
Each year about 40,000 infants are born in the United States
with a heart defect. While new technology and surgical innovations have
made a tremendous difference in the outcome and quality of life of these
young patients, the harsh reality remains that an infant born with heart
disease often faces a future of repeated surgeries to replace an outgrown
or a congenitally missing heart valve.
Richard Hopkins, MD, Director, Cardiac Surgery Research Laboratories
Chief, Adult/Adolescent Congenital Cardiac Surgery and Professor
developing a novel procedure that would enable the use of a patient’s own
cells to fashion a new, bioengineered heart valve. Because the valve would
be comprised of living tissue derived from the child’s own cells, it would
grow and repair itself, and the child’s immune system would accept the
material as its own.
“The overall goal of the Cardiac Research Laboratory of the Ward
Family Center for Congenital Heart Disease, as a translational research
laboratory, is to make solid, safe solutions that improve the quality of life for
our patients. It’s a ‘bench to bedside’ approach we think will revolutionize
heart valve replacement,” says Dr. Hopkins.
Tissue engineering, as defined by Dr. Hopkins, involves applications
to repair or replace structural tissues (for example, bone, cartilage, blood
vessels, etc.) with cells combined with biological scaffolds that effectively
function on the basis of their mechanical and biological properties. With
numerous projects underway, including tissue-engineered heart valves
and trachea, heart muscle replacement, cell biology and safety criteria of
engineered tissues, as well as patient advocacy, the laboratory is focused
on creating scientific methods that are safe, reproducible, that will enhance
and ultimately, lengthen the lives of patients.
“At the end of the day, we’re going to be successful in cardiac tissue
engineering and also serve as advocates for our patients with the
introduction of safe clinical innovations,” Dr. Hopkins says.



Richard A. Hopkins, MD

of Surgery, University of Missouri-Kansas City School of Medicine, is

It was across the pond in
England, a year after finishing
medical school at Duke University
that Richard Hopkins, MD, learned
about fresh cadaveric human
valves being used as a conduit
replacement for children born
without heart valves. It was this
experience that sparked his interest in
tissue engineering, as approximately
eight out of every 1,000 children are
born with a congenital heart condition
requiring heart valve replacement.
Upon returning to the states, Dr.
Hopkins spent 10 years at Georgetown
University studying how to make such
human heart tissue better and more
durable. From there, Dr. Hopkins spent
11 years at Brown University, continuing
his studies on tissue engineering. In
2007, he joined the Cardiac Research
Laboratory of Children’s Mercy Hospital’s
Ward Family Center for Congenital Heart
Disease.
Dr. Hopkins is a recognized leader
in tissue engineering and has authored
two books “Cardiac Reconstructions
with Allograft Valves” and more recently,
“Cardiac Reconstructions with Allograft
Tissues.”
“I am passionate about the tissue
engineering research we’re doing–
Children’s Mercy is truly at the forefront
of conducting this life changing research
and that’s exciting,” says Dr. Hopkins.



New Researc h

Re-examining Diabetes Risks
High average glucose – or blood sugar – is the alleged culprit
causing much of the damage in the bodies of the millions of children
diagnosed with diabetes.
But based on recent molecular biology studies, Mark Clements, MD
PhD, Endocrinology, Assistant Professor of Pediatrics/Endocrinology,
University of Missouri-Kansas City School of Medicine, theorizes that the
focus on chronic hyperglycemia (high average blood sugar) may be wrong,
or least wrong to a degree.
“It is possible that high blood sugar on average over a long period of
time may not only fail to tell us the whole story, but may not be the most
important thing in determining our risk for complications in diabetes,” says
Dr. Clements. “The rise and fall of the glucose over the day may be the
biggest factor, or at least an equally important one.”
Funded by a Katharine Berry Richardson (KBR) award, Dr. Clements is
building something that doesn’t currently exist -- an animal model to study
the impact of glucose variability on chronic complications.
“We are building a model of glucose variability in the diabetic rat with
the goal of creating different treatment groups that allow us to look at
high glucoses on average versus glucose variability over many months and
how they each impact the development of chronic complications,” says Dr.
Clements.
This is all made possible thanks to new continuous glucose biosensor
monitoring technology that allows researchers to see glucose fluctuations
minute by minute.
Dr. Clements will also be looking at several additional outcomes
including markers of oxidative stress in the blood of these animals,
gene expression analysis of the white blood cells to look for markers
of cardiovascular inflammation, and physiologic markers for cataract
formation, proteinuria, hypertension, and tissue damage.
“As soon as we demonstrate the degree to which glucose variability
plays a role in complications, we’ll then be able to look at various
interventions in the oxidative stress response to see whether we can have
an impact on the rate of complications,” says Dr. Clements.
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Mark Clements, MD PhD

In the process of completing
his fellowship in Pediatric
Endocrinology, Mark Clements, MD
PhD, has not abandoned his first
interest in basic science, as he has
continued to stay involved through
his research in diabetes.
“I’m getting back to my roots I
guess, and one of the many things I’m
good at is taking a clinical problem and
developing a way to study it at a basic
science level or model level,” says Dr.
Clements.
Dr. Clements is a graduate of the
Medical Scientist Training Program at the
Washington University in St. Louis School
of Medicine. He also holds a doctorate
degree in Neuroscience.
“I’m involved in science because I’m
motivated to make a difference,” says
Dr. Clements. “Our research may impact
Type 1 and Type 2 diabetes, and Type 2
diabetes is one of the fastest growing
health problems around the world.
Anything we can do to make a difference
in the health of these patients could
have a huge effect, a huge impact.”

11

New Researc h

Individualizing Cancer Treatment
Despite the widespread use of cyclophosphamide to treat a wide
variety of cancers, relatively little is known about how it is metabolized
in infants and children. Some of the complicated metabolic reactions of
this drug cause tumor cells to die while others cause severe side effects.
Because the relationship between development, genetic make-up and drug
exposure remains largely unexplored, pediatricians may not be giving the
Understanding how cyclophosphamide is metabolized in children
is the focus of a study directed by Andrea Gaedigk, MS, PhD, Clinical
Pharmacology and Jignesh Dalal, MD, Bone Marrow Transplantation,
experts in the fields of pharmacogenetics and pediatric oncology. It
is supported by the Tom Keaveny Endowed Fund for Pediatric Cancer
Research.
“The amount of enzymes that metabolize certain drugs varies
considerably from person to person, which is mostly due to a person’s
genetic make-up,” says Dr. Gaedigk. “An additional layer of complexity is
that many of these drug-metabolizing enzymes ‘turn on’ at variable times
after birth, usually during the first year of life. Choosing the right drug and
the right dose in order to maximize benefits while limiting adverse effects
remains a huge challenge, especially in our youngest patients.”
According to Dr. Gaedigk, there is still a big knowledge deficit about
how drugs work in very, very young children that drives her inquiry into the
variability of these enzymes.
“Children are not just little adults,” says Dr. Gaedigk. “This research
will help give us a better understanding of how this drug should be dosed
for children. Since it can make them very sick, every bit that we can reduce
the amount they get and still receive the benefits will help.”
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Andrea Gaedigk, MS, PhD

best possible dose to their patients.

Getting in on the ground floor of
a revolutionary new field opened up
a fascinating career path for Andrea
Gaedigk, MS, PhD. While pursuing
her doctorate in her native Germany,
she had the opportunity to work with
Michel Eichelbaum, MD, one of the early
pioneers of pharmacogenetics.
“It was an emerging field at that time
and very exciting,” says Dr. Gaedigk. “I
had a chance to get in and I jumped on
it.”
Dr Gaedigk’s major research interest
is how genetic factors affect drug
metabolism. She is involved in a number
of studies spanning a variety of drugs,
including codeine (pain medication),
dextromethorphan (a component of
cold medication) and warfarin (an
anticoagulant).
Looking ahead, the promise that
pharmacogenetics holds for the future
seems even greater now than when she
first entered the field.
“The ultimate goal is to get the right
drug to the right person at the right
dose,” says Dr. Gaedigk, who chairs the
Basic Science Research Committee.
“We’re generating tremendous amounts
of data to help us know how to do that.
The challenge is understanding what it
all means.”
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New Researc h

Assessing Antihistamine Effectiveness
Antihistamines are the common remedy to combat the release
of histamine in the body, which is the cause of many allergy symptoms
such as itching eyes and runny, watery nose. Allergies affect about 50
million American children, most of whom are treated with some form of
antihistamine.
Without intervention using antihistamines, the termination of the
histamine effects is dependent upon the activity of specific enzymes in
the body that degrade histamine. The activity of these enzymes is now
known to be under genetic control which may, in part, explain differences in
severity of allergy symptoms between individuals.
To gain a better understanding of how genetics affects histamine
breakdown, Bridgette Jones, MD, Allergy/Asthma/Immunology specialist
and Assitant Professor of Pediatrics, University of Missouri-Kansas City
School of Medicine, is investigating a new technique to assess histamine
response in the skin called histamine iontophoresis with laser Doppler
flowimetry. Her study is funded by a Katharine Berry Richardson (KBR)
grant.
“We are performing this technique on a group of patients to discern if
skin blood flow response to histamine iontophoresis as assessed via the
laser Doppler technique could be a surrogate marker for altered histamine
metabolism in relation to histamine pharmacogenetics,” says Dr. Jones.
“It would be great if we could develop a screening tool that we could use
clinically to look at patients and see who would benefit from antihistamines
or more aggressive allergy therapies such as immunotherapy,”
Histamine iontophoresis with laser Doppler flowimetry uses a low
electrical current to painlessly drive histamine into the skin and into the
small blood vessels of the outer skin layer. A low-energy laser positioned
over the skin can directly measure the response to the histamine as
indicated by blood flow to the site. This technique delivers a fixed dose of
histamine which can be measured in a dynamic and continuous fashion.
“A more standardized technique would be helpful clinically and allow us
to better evaluate antihistamines in the future,” says Dr. Jones.
14

Bridgette Jones, MD

As an asthma/allergy specialist,
Bridgette Jones, MD, was intrigued
by patients who received standard
therapy, but for some reason,
didn’t get better, no matter what
medication they received.
“Sometimes we would assume
these patients were not taking their
medications, but now we know that
because of their genes, they may be
unable to benefit from the medication
like other patients,” says Dr. Jones.
It was the impact of genetics on
asthma and allergies that got Dr. Jones
interested in pursuing a fellowship in
clinical pharmacology.
“The study of pharmacogenetics
will allow the opportunity to provide
therapies for patients that would benefit
them the most,” says Dr. Jones. “Right
now we put a patient on medicine for
a period and then have them come
back to see if it works. Applying
pharmacogenetics, we might obtain
a blood sample and determine which
medication they would benefit most from
and get them on the right therapy right
away.”
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New Researc h

Understanding Chronic Kidney Disease
With more than 26 million Americans now suffering from
chronic kidney disease, researchers are urgently seeking to better
understand the risk factors underlying this condition.
Children’s Mercy is one of the two clinical coordinating centers for the
first nation-wide study of children with chronic kidney disease. Funded
by the National Institutes of Health, a consortium comprised of 43
participating centers is looking at factors that influence the progression of
kidney disease and its complications in children.
Under the direction of co-principal investigator Bradley A. Warady, MD,
of Missouri-Kansas City School of Medicine, the study is following a cohort
of nearly 600 children through annual visits in which they are tracking
cardiovascular health, growth and neurocognitive function.
“Most of the children we are following presented with mild to moderate
kidney disease,” says Dr. Warady. “Some get worse, and others don’t. An
important goal of the study is to try to determine the reasons behind the
two different outcomes.”
The study is already yielding new information about the interaction of
known risk factors and disease progression. It has also shown associations
between a low glomerular filtration rate—the common measurement of
kidney function—and complications of chronic kidney disease such as
growth failure, anemia, high blood pressure and attention deficits.
According to Dr. Warady, the fact that a large number of the children
had a low birth weight has been an unexpected finding. In addition, the
study has revealed the frequent presence of masked hypertension—high
blood pressure that is only detected at night through the use of 24-hour
ambulatory blood pressure monitoring.
“If these kids were only evaluated during the day at an office visit, there
would be no evidence of elevated blood pressure,” says Dr. Warady. “Our
findings provide important evidence supporting the routine use of 24-hour
blood pressure monitoring in all children with chronic kidney disease.”

16

Bradley A. Warady, MD

Section Chief of Nephrology and Associate Chair of Pediatrics, University

Ever since he was a young boy,
Bradley A. Warady, MD, has known
what profession he wanted to
pursue. During a lengthy illness at age
9, his pediatrician became a role model
for him.
“It wasn’t so much his knowledge,
but it was his caring personality that
impressed me,” says Dr. Warady, who
serves as Director of Dialysis and
Transplantation at Children’s Mercy as
well as Associate Chair of Pediatrics at
the University of Missouri—Kansas City
School of Medicine. “I knew then that I
wanted to be a pediatrician.”
That same spirit of compassion for
patients helped to steer him toward
Nephrology as a subspecialty when he
was in medical school and during his
residency. Not only was he intrigued by
the evolution of care in the field, he saw
an opportunity for a career that would
allow a deeper level of interaction with
patients.
“I enjoy the intellectual challenges
of treating children who have kidney
disease,” says Dr. Warady. “But more
importantly, nephrology allows you to
develop long-term personal relationships
with patients and their families. That’s
what has meant the most to me.”

A new study led by Brad Warady, MD
could help doctors better understand the
progression of chronic kidney disease in
patients like Lucas Moad.
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Awards and ho n ors

Kreamer Research Excellence Award
Andrea Gaedigk, PhD
Clinical Pharmacology
The Kreamer Research Excellence Award is presented each year to a
member of the Children’s Mercy staff whose work shows evidence of
continuing excellence in research impacting pediatric health care. The
award provides $5,000 to be spent at the recipient’s discretion on his or
her research projects. Nominees for this award must have been full-time
active members of the medical/dental or research staff of Children’s Mercy
for at least five years; must hold the academic rank of Associate Professor
or above at the University of Missouri – Kansas City; must perform research
that has an impact on improving health care for children; must have their
research published in peer-reviewed journals; and must show evidence of
continuing excellence in research. The Department of Medical Research
solicits nominations and asks selected reviewers to vote for an awardee.

18

Andrea Gaedigk, MS, PhD

John and Marion
Kreamer Research
Excellence Award
2006 Susan Abdel-Rahman, PharmD
2005 Denise Dowd, MD
2004 George Gittes, MD
2003 Jill Jacobson, MD
2002 Gregory Kearns, PharmD, PhD
2001 J. Steven Leeder, PharmD, PhD
2000 Wayne Moore, MD
1999 William Truog, MD
1998 Bradley Warady, MD
1997 Uri Alon, MD
1996 Stanley Hellerstein, MD
1995 Robert Hall, MD
1994 Jay Portnoy, MD
1993 Donald Thibeault, MD

19

Awards and ho n ors

PAUL HENSON IMMUNOLOGY RESEARCH
AWARD
Tarak Srivastava, MD
Nephrology
Assistant Professor of Pediatrics, UMKC School of Medicine
This award is presented yearly to a Children’s Mercy researcher to further
promising, ongoing research in pediatric immunology. Dr. Srivastava is
studying the role of the toll-like receptor part of the innate immune system
in the damage done to special kidney cells called podocytes in children
with minimal change disease, a relatively common childhood kidney
disease.

Tarak Srivastava, MD
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Paul Henson
Pediatric
Immunology Award
2006 Susan Abdel-Rahman, PharmD
2005 Lanny Rosenwasser, MD
2004 Wayne Moore, MD
2003 Wayne Moore, MD
2002 Wayne Moore, MD
2001 Wayne Moore, MD
2000 Jill Jacobson, MD
1999 Jill Jacobson, MD
1998 Jill Jacobson, MD
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Awards and ho n ors

THE CROSS FOUNDATION CLINICAL
SCHOLAR AWARD IN BEHAVIORAL
MEDICINE
Mark Connelly, PhD
Pain Management and Developmental Medicine & Behavioral Sciences
Assistant Professor of Pediatrics, UMKC School of Medicine
The Cross Foundation Clinical Scholar Award in Behavioral Medicine
was established to provide competitive, intramural grants to promising
Children’s Mercy researchers seeking to launch or expand their research
in behavioral medicine, including psychiatry, developmental medicine, and
outcome-based research. Dr. Connelly received support for his project
to study whether the use of integrative methods of pain management in
children prior to scoliosis surgery reduces pain and improves recovery
during hospitalization, as well as how it affects pain and functioning after
discharge .

22

Mark Connelly, PhD

23

Awards and ho n ors

TOM KEAVENY ENDOWED FUND FOR
PEDIATRIC CANCER RESEARCH
Andrea Gaedigk, PhD
Clinical Pharmacology

Jignesh Dalal, MD
Bone Marrow Transplantation
Assistant Professor of Pediatrics, UMKC School of Medicine

The Tom Keaveny Endowed Fund for Pediatric Cancer Research supports
peer-reviewed research of faculty or professional staff which expands
knowledge of the treatment and care of children with cancer. Dr. Dalal
and Dr. Gaedigk were given the award to support their work on better
understanding how the body metabolizes Cyclophosphamide, a common
cancer treatment while minimizing the immediate and long-term toxic
effects of chemotherapy.

24

Jignesh Dalal, MD

cancer drug, with the ultimate goal of better individualizing and maximizing

Andrea Gaedigk, PhD
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Awards and ho n ors

WILLIAM RANDOLPH HEARST
ENDOWMENT
Mark Connelly, MD
Pain Management and Developmental
Medicine & Behavioral Sciences
Assistant Professor of Pediatrics, UMKC School
of Medicine

Ben Pieters, DO
Anesthesiology
Assistant Professor of Pediatric Anesthesiology,
UMKC School of Medicine

Each spring and fall, an internal competition is held for the Katharine
Berry Richardson (KBR) awards. Among the proposals submitted for
the competition, the two top-rated projects are designated the William
Randolph Hearst Endowment Fund awardees and receive a portion of
their support from this fund. Dr. Connelly was honored for his work on
empirical evaluation of self-report pain scales as indicators of treatment
response following surgery. Dr. Pieters was awarded for his study of early
administration of fresh frozen plasma to reduce blood loss during surgery
for craniosynostosis.
26

William Randolph
Hearst Endowment
2006

Roger Gaedigk, PhD
Chengpeng Bi, PhD
Heather Newkirk, PhD

2005 Chetanbabu Patel, MD
Kathleen Neville, MD, MS

2004

Mary Moffatt, MD
Heather Newkirk, PhD
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Awards and ho nors

RESEARCH DAYS AWARDS
As part of the hospital’s ongoing commitment to pediatric research and
education, each year Children’s Mercy hosts Research Days presentations
by residents and fellows. A panel of judges confers Research Days awards
on the presenters of the best papers.

Erik Mikkelsen, MD
Faculty Mentors: Ken Wible, MD and Rangaraj
Selvarangan, PhD
Cerebrospinal Fluid Characteristics of Enterovirus
Reverse Transcriptase-PCR Positive vs. Negative
Specimens

Christina Peacock, MD
Faculty Mentor: Felix Okah, MD
Trends in Overweight/Obesity and Excessive Weight
Gain for BMI Among Pregnant Teenagers

Mukta Sharma, MD
Faculty Mentor: Alan Gamis, MD
Uniform Approach Better Defines Natural History of
Transient Myeloproliferative Disorder (TMD) In Down
Syndrome (DS) Neonates: Outcomes From Children’s
Oncology Group (COG) Study A2971

Sean Sweeney, DO
Faculty Mentor: Howard Kilbride, MD
Hypercarbia May Be More Predictive Than
Supplemental O2 at 36 Weeks’
Postmenstrual Age for Later Pulmonary Morbidity in
Preterm Infants
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SARAH MORRISON
STUDENT RESEARCH
AWARDS
The Sarah Morrison Student Research
Awards are presented by the University
of Missouri-Kansas City School of
Medicine to medical students who
pursue basic or clinical research under
the guidance of faculty mentors.

Spenser Menees
University of Missouri-Kansas City
School of Medicine
Faculty Mentor: Geetha Raghuveer, MD
Variation in Carotid Artery Intima –
Media Thicknesses during the Cardiac
Cycle

Joseph Le
University of Missouri-Kansas City
School of Medicine
Faculty Mentor: Geetha Raghuveer, MD
Measuring the Vascular Age of Children
with Familial Hypercholesterolemia and
Mixed Dislipidemia

Dr. Geetha Raghuveer reviews research
abstract information with Sarah Morriison
Fellowship Award recipients Joseph Le
(left) and Spencer Menees (right).
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endowed chairs
The Marion Merrell Dow/Missouri Chair in Pediatric Clinical Pharmacology
J. Steven Leeder, PharmD, PhD
Est. 1995

The Joseph Boon Gregg/Missouri Chair in Pediatric Cardiac Surgery
Gary Lofland, MD
Est. 1997

The William R. Brown/Missouri Chair in Medical Genetics and Molecular Medicine
Vacant
Est. 1997

The Dee Lyons/Missouri Chair in Pediatric Immunology Research
Lanny Rosenwasser, MD
Est. 1998

The Thomas Holder/Keith Ashcraft Chair in Pediatric Surgical Research
Vacant (pending)
Est. 2000

The Sosland Chair in Neonatal Research
William Truog, MD
Est. 2001

The Marion Merrell Dow Chair in Pediatric Pharmacogenomics
Vacant
Est. 2002

Joyce C. Hall Distinguished Professor of Pediatrics
Kevin Kelly, MD
Est. 1967

The Katharine B. Richardson Chair in Pediatric Surgery
George Whitfield Holcomb III, MD
Est. 1973

The Jerry A. Smith Chair in Pediatrics
Vacant
Est. 1985

The Dr. Rex and Lillian Dively Chair in Pediatric Orthopedic Surgery
Bradley Olney, MD
Est. 1989

The Ernest L. Glasscock, MD, Chair in Pediatric Education and Research
Stanley Hellerstein, MD
Est. 1990

The Marion Merrell Dow/Missouri Chair in Pediatric Medical Research
Gregory L. Kearns, PharmD, PhD
Est. 1995
30

Research Council Members
Randall L. O’Donnell, PhD
President and CEO
Research Council Chairman

Kim Brown

Carol Kemper, RN, MSN, CPHQ

Senior Director, Quality Management

Sandra Lawrence

Director, Audit and Advisory Services

Executive Vice President
Chief Financial Officer

V. Fred Burry, MD

Gary Pettett, MD

Executive Vice President
Executive Medical Director
Professor of Pediatrics, UMKC

Karen Cox, RN, PhD

Executive Vice President,
Co-Chief Operating Officer
Assistant Dean for Clinical Partnerships, UMKC School of
Nursing

Andrea Gaedigk, PhD

Pediatric Pharmacology and Medical Toxicology

Joe Galeazzi

Vice President, Medical Administration

Gregory L. Kearns, PharmD, PhD

Department Chair, Medical Research
The Marion Merrell Dow/Missouri Endowed Chair in
Medical Research
Professor, Pediatrics and Pharmacology, UMKC
Chairman, Department of Medical Research

Kevin J. Kelly, MD

Pediatrician-in-Chief
The Joyce C. Hall Distinguished Professor of Pediatrics
Professor and Chair, Department of Pediatrics
Associate Dean, UMKC School of Medicine

Chairman, Institutional Review Board
Director, Office of Research Integrity
Associate Dean, Academic Affairs, UMKC
School of Medicine
Professor of Pediatrics, UMKC

Robin Rusconi, JD

Director, Medical Research Administration

Vidya Sharma, MBBS

Dermatology Section
Professor of Pediatrics, UMKC School of
Medicine

Jo Stueve

Executive Vice President
Co-Chief Operating Officer

Bradley Warady, MD

Nephrology Section Chief
Director of Dialysis and Transplantation
Professor and Vice-Chair, Department of
Pediatrics, UMKC

Terry Weathers

Vice President of Finance/Controller
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Areas of Clinical Research
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Acid Reflux Disease
Adrenal Gland Disorders
Allergies and Allergic Rhinitis
Anemia
Anti-Emetic Therapy
Anti-Fungal Treatment
Anti-microbial Stewardship Program
Antigen Challenge Testing
Asthma
Attention Deficit Hyperactivity Disorder
Autism
Bioengineered Personal Heart Valves
Bladder Disorder
Bone Marrow Transplant

Hemophilia
Hepatitis
Hormone Deficiency
Hypertension
Ideopathic Nephrotic Syndrome
Immune Tolerance Induction
Infectious Diseases
Influenza
Intra-Ocular Lens
Iron Metabolism
Irritable Bowel Syndrome
Juvenile Rheumatoid Arthritis
Lymphomas
McCune Albright Syndrome

Bronchiolitis
Catheter Flow
Childhood Cancers
Chronic Abdominal Pain in Children
Chronic Lung Disease
Chronic Pain
Coagulation Disorders
Constitutional Delay of Growth & Puberty
Cystic Fibrosis
Cytogenetics
Device Studies
Diabetes Mellitus Types I & II
Diagnostic Imaging
Diagnostic Kits
Dialysis
Dietetics
Digestive Disorder
Drug Metabolism
Dyspepsia
Eczema
Endocrinology
Epilepsy
Fecal Retention
Gender Differences in Systemic Lupus
Genetic Disease
Genetics
Genotyping
Glaucoma
Graft vs. Host Disease
Growth Factors
Growth Hormone Deficiency
Gynecomastia

Meningitis
Metabolic Disorders
Migraine
Muscular Dystrophy
Neonatal Nutrition
Obesity
Organ Transplantation
Otitis Media
Pain Treatment, Post Surgical
Partial Liquid Ventilation
Pharmacogenetics
Pharmacokinetics
Pneumonia
Psychiatry and Behavioral Disorders
Pulmonary Disease in Critical Care
Patients and Newborns
Pulmonary Hypertension in Newborns
Quality of Life Scale
Rehabilitation & Physical Therapy
Renal Disease
Renal Transplantation
Respiratory Disease in Newborns
Respiratory Tract Infections
Sedation in Critical Care Patients
Seizure Disorder
Sepsis
Sickle Cell Disease
Skin and Soft Tissue Infections
Tissue Engineering
Turner Syndrome
Ulcerative Colitis
Visual Acuity

Summer Scholars
2007
Through the Summer Scholars program,
Children’s Mercy provides college
students with experience in pediatric
research. During the summer of 2007,
10 scholars worked with researchers on
various projects. We are glad to provide
these students an opportunity to explore
their interest in research careers.

The 2007 Summer Scholars were:
Dan Aubin, University of Missouri-Rolla
Kelli Baalman, Rockhurst University
Jacob Brown, Creighton University
James Bush, Kansas State University
Bonnie Carsten, Evangel University
Amy Hamilton, University of Miami
(Florida)
Nathan Johnson, Evangel University
Katherine Klockau, University of Kansas
Alyssa N. Morse, Washburn University
Joseph Pacheco, Northwest Missouri
State University
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Research Facts and Figures

Source of Sponsored Research Funds - 2007

Research Expenditures from External Funding
2007
Federal

5,304,104

Foundation

1,189,002

Industry

825,420

State

234,543

Local/Corporation

234,202

Total

$7,787,271

Publications and Presentations
Number of presentations/posters

192

Number of publications

266

Total for 2007

458

Visit our Web site at www.childrensmercy.org/research for additional
information and complete listings of publications and presentations.
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Investigational Review Board
Our vision for creating a healthier future for all children encompasses the
health, safety and general welfare of every child we see at Children’s Mercy.
As we approach research with a view for improving and advancing care for
all children, we are always respectful of the patient’s and family’s present
needs and wishes.
To ensure that the safety and welfare of children are always at the forefront,
all research studies involving the participation of children are reviewed,
approved and monitored by our multidisciplinary Pediatric Institutional
Review Board (IRB). In 2007, the IRB approved 199 new studies and
conducted 1,011 actions pertaining to ongoing studies and other research
related activities.
Additional protection of patient privacy rights also is afforded by the Office
for Research Integrity (ORI), which serves as the primary office on matters
relating to the protection of human research subjects, education for the
responsible conduct of research, research misconduct, laboratory animal
welfare, radiation, and bio-safety in research. The ORI functions to promote
and assure the ethical conduct of research in conformance with federal
regulations and institutional policies.

CY2007
New Projects	199
Continuing Oversight 	1,011
Total Reviews	1,210
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Medical Research
2401 Gillham Road
Kansas City, MO 64108
(816) 234-3961
www.childrensmercy.org/research

In Academic Affiliation with the University of
Missouri-Kansas City School of Medicine.
AA/EOE
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